 LEXINGTON, Mass., April 15, 2021 PRNewswire -- Pulmatrix, Inc. NASDAQ: PULM, a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSETM technology, today announced that it will host a key opinion leader KOL webinar on PUR3100, Pulmatrixs orally inhaled dihydroergotamine DHE therapy for the treatment of acute migraine, on Friday, April 23, 2021 at 10:00am Eastern Time. 